Teaching AI to Design Better Medicines: A-Alpha Bio + Novo Nordisk

A-Alpha Bio and Novo Nordisk are partnering to accelerate protein drug discovery by generating high-throughput experimental data needed to train AI models.

The Challenge: Traditional methods for studying protein interactions are slow and only able to test a small number of interactions at a time, limiting the data available for AI. Understanding how strongly protein drugs may bind to targets or other proteins in the body is crucial for designing new treatments.

The Solution: A-Alpha Bio's AlphaSeq technology simultaneously measures millions of protein-to-protein binding interactions, rapidly generating the massive, quantitative experimental datasets that will make AI protein models better. We were early investors in A-Alpha Bio and are excited to see this next step in their journey.

The Impact: Novo Nordisk will use this custom AlphaSeq data to train its AI for discovering and optimizing protein drugs, aiming to better predict how strongly protein drugs bind to disease targets. This improved modeling is a critical piece in progress toward protein drug candidates that are more likely to hit their targets and advance out of early discovery.

This powerful combination shows how some of the most exciting advances may come from combining algorithms and experimental biology with the right partners to solve real problems that matter. 

We look forward to seeing the innovative new treatments this partnership helps make possible.